Corcept Therapeutics Incorporated Revenue 2009–2025
Corcept Therapeutics Incorporated annual/quarterly revenue history and growth rate from 2009 to 2026. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sale of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
- Corcept Therapeutics Incorporated revenue for the quarter ending March 31, 2026 was 164.9 M, a 4.89% increase year-over-year.
- Corcept Therapeutics Incorporated revenue for the twelve months ending March 31, 2026 was 724.2 M, a 17.42% increase year-over-year.
- Corcept Therapeutics Incorporated annual revenue for 2025 was 761.4 M, a 12.79% increase from 2024.
- Corcept Therapeutics Incorporated annual revenue for 2024 was 675.0 M, a 39.94% increase from 2023.
- Corcept Therapeutics Incorporated annual revenue for 2023 was 482.4 M, a 20.04% increase from 2022.
- Corcept Therapeutics Incorporated annual revenue for 2022 was 401.9 M.
Corcept Therapeutics Incorporated (CORT) — Frequently Asked Questions
Corcept Therapeutics Incorporated (CORT) is a publicly traded US company. It has a market capitalization of $9.75B. In fiscal 2025 it reported revenue of $761M and net income of $100M. Explore CORT's stock price, financial statements, earnings history, margins and key ratios below.
What is Corcept Therapeutics Incorporated's market cap?
Corcept Therapeutics Incorporated (CORT) has a market capitalization of $9.75B.
What is the CORT stock price?
CORT trades at $81.22 (+3.97% on the day).
How much revenue does Corcept Therapeutics Incorporated make?
Corcept Therapeutics Incorporated reported revenue of $761M in fiscal 2025.
Is CORT profitable?
In fiscal 2025, Corcept Therapeutics Incorporated reported net income of $100M.